CD86 and common variable immunodeficiency: Analysis of nine CVID patients revealed that IVIg treatment significantly increases the percentage of HLA-DRlow CD14 + cells (Fig. 3C), an increase that coincided with reduced cell surface expression of HLA-DR (Fig. 3D) and of the M-MDSCs markers CD16, CD86, CX3CR1 and CCR5 (Fig. 3E).